engleski

Comparative Analysis of Azithromycin and Doxycycline Efficacy in the Treatment of Female Patients with Acute Urethral Syndrome Caused by Ureaplasma Urealyticum

The aim of this opened, controlled study was to determine the frequency of U.urelayticum as a causative pathogen of the acute urethral syndrome in female patients and to compare the clinical and bacteriological efficacy of azithromycin with doxycycline regimens. The study included 164 patients. U.urealyticum was isolated from urethral swab specimens. The study included patients older than 16 years who had not taken any antimicrobials 14 days prior to enrolment. Chlamydia trachomatis, gonococcal, Trichomonas vaginalis, Candida infections, and syphilis were excluded. Azithromycin (500 mg od/6 days) was administered in 50 patients in whom the isolated strains were susceptible to erythromycin in vitro. Doxycycline was administered in 114 patients in whom the isolated strains were susceptible to doxycycline (50 patients received doxycycline bid/14 days, and 64 patients 100 mg doxycycline bid/7 days). The same therapy applied to the patients' sexual partners. Clinical and bacteriological efficacy was evaluated 2-3 weeks after completion of therapy. U.urealyticum caused urethral syndrome in 34.1% of patients. Clinical cure was attained in 88% and eradication of U.urealyticum in 94% azithromycin-treated patients, and these results do not statistically differ from the results with doxycycline 100 mg bid/14 days (94% and 96% respectively). Lower rates of clinical cure (73.4%) and eradication (79.9%) resulted after doxycycline 100 mg bid/7 days. Azithromycin 500 mg od for 6 days and doxycycline 100 mg bid for 14 days showed high clinical and bacteriological efficacy and proved superior to 7.day doxycycline therapy in patients with acute urethral syndrome caused by U.urealyticum.

U.urelayticum; azithromycin

nije evidentirano